Project Grant W81XWH1910664

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

Federal Cooperative Agreement Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Medical University of South Carolina a $688,047 Cooperative Agreement on September 1, 2025, to conduct the WINDSURFER trial (WIN Ratio Analysis to Determine a Strategy of Non-Invasive Support for Respiratory Failure in the Emergency Department). This clinical research initiative will extend through August 31, 2031, and addresses a critical gap in emergency care by comparing the effectiveness...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $2.39 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the SPARC Trial (The Effect of Specialty Care on Recovery from Cardiac Arrest). The award, effective September 1, 2025 through August 31, 2026, funds a randomized controlled trial designed to evaluate whether transfer to a specialty cardiac arrest center improves...

Federal Cooperative Agreement Summary Award Details: The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Cooperative Agreement valued at $1,535,439 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, with completion targeted for December 31, 2026. The award funds the WINDSURFER Trial (WIN Ratio Analysis to Determine a Strategy of Non-Invasive Support for Respiratory Failure in the Emergency Department), a multi-site...

Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $664,331 Cooperative Agreement to the University of Virginia on September 20, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the STARS Trial (Steroids and Enhanced Antibiotics for the Treatment of Patients in Africa with Refractory Sepsis). The trial addresses sepsis treatment in sub-Saharan Africa, where tuberculosis (TB) is the leading infectious cause and...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University in the City of New York $427,256 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 15, 2025, with completion targeted for August 31, 2027. This Project Grant supports a feasibility and protocol development study for "Bilevel Positive Airway Pressure (BPAP) for Severe Pediatric Asthma Exacerbations: A Randomized, Controlled Trial." The research...

Federal Grant Award Summary Wake Forest University Health Sciences received a $1.51M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with completion anticipated by May 31, 2030. The award funds a randomized clinical trial and biomarker research initiative investigating the dysfunctional renin-angiotensin-aldosterone system (RAAS) in septic shock. The study compares the...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $243,750 to the University of Pennsylvania on August 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a secondary analysis of the NHLBI Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) trial. The project will deliver research findings evaluating plasma renin as a predictive and prognostic biomarker in sepsis-induced hypotension, with...

Federal Grant Award Summary Boston Children's Hospital received a $279,644 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion scheduled for August 31, 2027. The grant funds research to develop and validate time to return of spontaneous circulation (ROSC) as a novel primary outcome measure for pediatric in-hospital cardiac arrest (P-IHCA) clinical trials. The research...

SMART-SEPSIS Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1.44 million under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, San Francisco on August 21, 2025, for the SMART-SEPSIS project. This four-year initiative (through May 31, 2029) develops sequential machine learning algorithms to identify community-onset lung sepsis patients who will benefit from immediate application of the Hour-1 Sepsis Bundle—the...